AEterna Zentaris (AEZS)
(Delayed Data from NSDQ)
$5.35 USD
-0.05 (-0.93%)
Updated Jul 26, 2024 02:51 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AEZS 5.35 -0.05(-0.93%)
Will AEZS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AEZS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AEZS
Aeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue Estimates
BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates
AEZS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue Estimates
Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates
Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug
Other News for AEZS
Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders
Mannatech Announces Appointment of James Clavijo as Chief Financial Officer
Aeterna Zentaris Release: A Technical Glitch?
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
Aeterna Zentaris Wraps Up Key Pediatric Trial